HKUCTR-2788Not yet recruiting
Untitled Trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)
<AstraZeneca Hong Kong Limited>Phase 3HKU CLINICAL TRIALS REGISTRYdrug
VerifiedHKU CLINICAL TRIALS REGISTRY
Study focus
- Disease/Condition
- Neoplasm
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- <AstraZeneca Hong Kong Limited>
- Location
- China
Timeline & enrollment
- Phase
- Phase 3
- Start date
- N/A
- End date
- Nov 03, 2022
ICD-10 classifications
NeoplasmsBenign neoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasm: Other specified sites
Data source
- Registry
- HKU CLINICAL TRIALS REGISTRY
- Trial ID
- HKUCTR-2788
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for HKUCTR-2788 through Pure Global AI's free database. This Phase 3 trial is sponsored by <AstraZeneca Hong Kong Limited> and is currently Not yet recruiting. The study focuses on Neoplasm.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to HKU CLINICAL TRIALS REGISTRY data, helping medical device and pharmaceutical companies navigate clinical research efficiently.